NMPA Approves Ecnoglutide for Chronic Weight Management in Adults with Overweight or Obesity
- nuaxia
- 2 days ago
- 2 min read
China authorises the first cAMP-biased GLP-1 receptor agonist for obesity, following robust Phase III SLIMMER trial results.
The National Medical Products Administration (NMPA) has approved ecnoglutide for chronic weight management in adults with overweight or obesity, supported by Phase III SLIMMER trial data showing a placebo-adjusted mean weight reduction of 15.1% at 48 weeks and 92.8% of patients achieving clinically meaningful ≥5% weight loss.
This marks the first global approval of a cAMP-biased GLP-1 receptor agonist for obesity, providing a potent new option for sustained weight loss with efficacy comparable to semaglutide (Wegovy).
Alert Type | Drug Approval (NMPA) |
Drug/Device Name | Ecnoglutide |
Indication | Chronic weight management in adults with overweight or obesity |
Therapy Area(s) | Endocrinology / Metabolic Disease |
Geography | China (NMPA) |
What Changed | The NMPA approved ecnoglutide for chronic weight management in adults with overweight or obesity, following Phase III SLIMMER trial data showing a placebo-adjusted mean weight reduction of 15.1% at 48 weeks and 92.8% of patients achieving ≥5% weight loss. |
Clinical Relevance | Introduces the first cAMP-biased GLP-1 receptor agonist for obesity in China, providing a potent new option for sustained weight loss with efficacy comparable to semaglutide (Wegovy). |
Source Link | |
Date | 27-Feb-2026 |
Status | Draft |
Notes | Second regulatory authorisation (previously approved for T2D as Xianyida, Jan 2026); Pfizer secured commercialisation rights in China in a $495M deal; demonstrates continued weight loss at 48 weeks without plateau; first global approval for a cAMP-biased GLP-1 receptor agonist in obesity. |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments